***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: OBJECTIVES Advanced gastric cancer ( AGC ) patients have a poor prognosis . The best benefit of chemotherapy is usually achieved by first line setting . Very few studies have compared combination regimens . This study was design ed to compare two combination regimens . METHODS Patients with advanced gastric cancer receiving first line chemotherapy were retrospectively collected , and divided into two groups , receiving DCF ( docetaxel , cisplatin and fluorouracil ) or ECF ( epirubicin , cisplatin and fluorouracil ) regimens . Data were collected for the retrospective analysis in a single center . RESULTS Eighty-six patients were eligible for analysis . Median overall survival ( OS ) was 10.0 months in the ECF group and 11.0 months in the DCF group ( p=0.31 ) . Median progression free survival ( PFS ) for ECF and DCF was equal at 6.0 months . Second line chemotherapy were administered in more than one third of patients . Both regimens had similar toxicity . CONCLUSIONS This is the first study investigating the outcomes of gastric cancer chemotherapy in this region . ECF and DCF regimens have similar efficacy and a similar tolerability profile for first line treatment of advanced gastric cancer . The decision of the first line chemotherapy in advanced gastric cancer could be improved with patient selection according to clinical parameters and molecular markers Study rationale , objectives , design , methods , and statistical considerations of an ongoing phase III study comparing S-1 alone versus the S-1/docetaxel combination are review ed . This study is a prospect i ve , multicenter , multinational , nonblinded , r and omized , phase III study of subjects with advanced gastric cancer . Subjects are to be r and omly assigned to 3-week cycles of Treatment Arm A ( docetaxel and S-1 ) or 6-week cycles of Treatment Arm B ( S-1 only ) . The primary objective of the study is to compare median overall survival of the test arm ( docetaxel and S-1 ) to the control arm ( S-1 only ) in subjects with advanced or recurrent gastric cancer . The secondary objectives of the study are to assess the time-to-tumor progression ( TTP ) , defined as time from r and omization to date of first documentation of progressive disease ( PD ) , to determine the clinical response ( RR ) , defined as the sum of complete response ( CR ) and partial response ( PR ) according to Response Evaluation Criteria in Solid Tumors ( RECIST ) , and to evaluate the safety of the two regimens . A total of 628 subjects ( 314 in each treatment arm ) will be enrolled . Subject enrollment began in September 2005 and lasts approximately 3 years . We have already enrolled 556 patients ( 88.5 % : Japan , 346 cases ; Korea , 210 cases ) from 103 centers ( Japan , 86 centers ; Korea , 17 centers ) between December 2005 and February 2008 . We are expecting full enrollment at the end of August 2008 . The JACCRO GC-03 study is now ongoing . After 2 years follow-up from full enrollment , in 2010 we will report the final results of this study Background : Docetaxel administered 3-weekly with cisplatin and 5-fluorouracil leads to better survival than does st and ard therapy in patients with oesophagogastric cancer , but leads to high rates of haematological toxicity . Weekly docetaxel is associated with less haematological toxicity . This r and omised phase II study tested weekly docetaxel-based combination chemotherapy regimens , with the aim of maintaining their activity while reducing toxicity . Methods : Patients with histologically confirmed metastatic oesophageal or gastric carcinoma were r and omised to receive weekly docetaxel ( 30 mg m−2 ) on days 1 and 8 , cisplatin ( 60 mg m−2 ) on day 1 , and 5-fluorouracil ( 200 mg m−2 per day ) continuously , every 3 weeks ( weekly TCF , wTCF ) ; or docetaxel ( 30 mg m−2 ) on days 1 and 8 and capecitabine ( 1600 mg m−2 per day ) on days 1–14 , every 3 weeks ( weekly TX , wTX ) . Results : A total of 106 patients were enrolled ( wTCF , n=50 ; wTX , n=56 ) . Response rates , the primary end point , were 47 % with wTCF and 26 % with wTX . Rates of febrile neutropenia were low in each arm . Median progression-free and overall survival times were 5.9 and 11.2 months for wTCF and 4.6 and 10.1 months for wTX , respectively . Conclusion : Weekly TCF and TX have encouraging activity and less haematological toxicity than TCF administered 3-weekly . Weekly docetaxel-based combination regimens warrant further evaluation in this disease OBJECTIVE Although docetaxel is active against gastric cancer , Grade 3 or 4 neutropenia occurs in the majority of patients in Japan when administered at 60 mg/m(2 ) every 3 weeks . To determine a more convenient and tolerable schedule than the tri-weekly schedule , we conducted a dose-escalation study of bi-weekly docetaxel . In this study , we investigated the maximum-tolerated dose and recommended dose . METHODS Patients with advanced gastric cancer who had received prior chemotherapy were enrolled between April 2004 and March 2007 . This study was design ed to evaluate the escalated dose of docetaxel starting at 35 mg/m(2 ) ( Level 1 ) given every 2 weeks . The dose was escalated in a stepwise fashion to 40 mg/m(2 ) ( Level 2 ) , 45 mg/m(2 ) ( Level 3 ) and 50 mg/m(2 ) ( Level 4 ) . RESULTS Fifteen patients completed at least two cycles of the therapy . Three episodes of Grade 3 neutropenia occurred in all patients and Grade 4 neutropenia was observed at Level 4 in six patients . Grade 3 or 4 thrombocytopenia and anemia were not observed . Grade 3 aspartate aminotransferase/alanine aminotransferase elevation ( n= 1 ) and Grade 3 stomatitis ( n = 1 ) were noted at Level 4 . There was no other Grade 3 or 4 non-hematologic toxicity . The definition of dose-limiting toxicities of this docetaxel schedule at Level 4 are Grade 4 neutropenia , Grade 3 aspartate aminotransferase/alanine aminotransferase elevation and Grade 3 stomatitis . CONCLUSIONS The maximum-tolerated dose of docetaxel when administrated following the bi-weekly schedule was 50 mg/m(2 ) and the recommended dose was 45 mg/m(2 ) . Bi-weekly administration of docetaxel may provide a better tolerated and efficacious use in gastric cancer Background The V325 study showed that docetaxel , cisplatin , and fluorouracil ( DCF ) prolonged overall survival ( OS ) of patients with advanced gastric cancer , but with a high incidence of dose-limiting toxicities . We investigated the efficacy and safety of a modified DCF ( mDCF ) regimen for Chinese patients with advanced gastric cancer . Methods Untreated advanced gastric cancer patients r and omly received docetaxel and cisplatin at 60 mg/m2 ( day 1 ) followed by fluorouracil at 600 mg/m2/day ( days 1–5 ; mDCF regimen ) or cisplatin at 75 mg/m2 ( day 1 ) followed by fluorouracil at 600 mg/m2/day ( days 1–5 ; CF ) every 3 weeks . The primary end point was progression-free survival ( PFS ) . The secondary end points were OS , overall response rate ( ORR ) , time-to-treatment failure ( TTF ) , and safety . Results In total , 243 patients were r and omized to treatment ( mDCF regimen 121 ; CF 122 ) . Compared with CF , the mDCF regimen significantly improved PFS and OS : the median PFS was 7.2 and 4.9 months , respectively [ hazard ratio ( HR ) 0.58 , log-rank P = 0.0008 ] , and the median OS was 10.2 and 8.5 months , respectively ( HR = 0.71 , P = 0.0319 ) . Additionally , the mDCF regimen improved the parameters used as secondary objectives : the ORR was 48.7 % with the mDCF regimen versus 33.9 % with CF ( P = 0.0244 ) ; the median TTF was 3.4 months with the mDCF regimen and 2.4 months with CF ( HR = 0.67 , P = 0.0027 ) . Grade 3 and grade 4 treatment-related adverse events occurred in 77.3 % of patients who received the mDCF regimen versus 46.1 % of patients who received CF ( P < 0.001 ) . Conclusions The mDCF regimen , compared with CF , significantly prolonged PFS and OS and enhanced ORR of Chinese patients with advanced gastric cancer .  The mDCF regimen achieved efficacy comparable to that of DCF but with fewer toxicities , which is appropriate for the Chinese population PURPOSE This r and omized phase II trial evaluated two docetaxel-based regimens to see which would be most promising according to overall response rate ( ORR ) for comparison in a phase III trial with epirubicin-cisplatin-fluorouracil ( ECF ) as first-line advanced gastric cancer therapy . PATIENTS AND METHODS Chemotherapy-naïve patients with measurable unresectable and /or metastatic gastric carcinoma , a performance status < or= 1 , and adequate hematologic , hepatic , and renal function r and omly received < or= eight 3-weekly cycles of ECF ( epirubicin 50 mg/m(2 ) on day 1 , cisplatin 60 mg/m(2 ) on day 1 , and fluorouracil [ FU ] 200 mg/m(2)/d on days 1 to 21 ) , TC ( docetaxel initially 85 mg/m(2 ) on day 1 [ later reduced to 75 mg/m(2 ) as a result of toxicity ] and cisplatin 75 mg/m(2 ) on day 1 ) , or TCF ( TC plus FU 300 mg/m(2)/d on days 1 to 14 ) . Study objectives included response ( primary ) , survival , toxicity , and quality of life ( QOL ) . RESULTS ORR was 25.0 % ( 95 % CI , 13 % to 41 % ) for ECF , 18.5 % ( 95 % CI , 9 % to 34 % ) for TC , and 36.6 % ( 95 % CI , 23 % to 53 % ) for TCF ( n = 119 ) . Median overall survival times were 8.3 , 11.0 , and 10.4 months for ECF , TC , and TCF , respectively . Toxicity was acceptable , with one toxic death ( TC arm ) . Grade 3 or 4 neutropenia occurred in more treatment cycles with docetaxel ( TC , 49 % ; TCF , 57 % ; ECF , 34 % ) . Global health status/QOL substantially improved with ECF and remained similar to baseline with both docetaxel regimens . CONCLUSION Time to response and ORR favor TCF over TC for further evaluation , particularly in the neoadjuvant setting . A trend towards increased myelosuppression and infectious complications with TCF versus TC or ECF was observed BACKGROUND We evaluated the feasibility and tolerability of triple- versus double-drug chemotherapy in elderly patients with oesophagogastric cancer . METHODS Patients aged 65 years or older with locally advanced or metastatic oesophagogastric cancer were stratified and r and omised to infusional 5-FU , leucovorin and oxaliplatin without ( FLO ) or with docetaxel 50 mg/m(2 ) ( FLOT ) every 2 weeks . The study is registered at Clinical Trials.gov , identifier NCT00737373 . FINDINGS One hundred and forty three ( FLO , 71 ; FLOT , 72 ) patients with a median age of 70 years were enrolled . The triple combination was associated with more treatment-related National Cancer Institute Common Toxicity Criteria ( NCI-CTC ) grade 3/4 adverse events ( FLOT , 81.9 % ; FLO , 38.6 % ; P<.001 ) and more patients experiencing a ≥10-points deterioration of European Organization for Research and Treatment of Cancer Quality of Life ( EORTC QoL ) global health status scores ( FLOT , 47.5 % ; FLO 20.5 % ; p=.011 ) . The triple combination was associated with more alopecia ( P<.001 ) , neutropenia ( P<.001 ) , leukopenia ( P<.001 ) , diarrhoea ( P=.006 ) and nausea ( P=.029 ) . ) . No differences were observed in treatment duration and discontinuation due to toxicity , cumulative doses or toxic 
    Output:
    
CONCLUSION With better ORR and DCR values , the DCF regimen seems to be more suitable for advanced gastric cancer than the ECF regimen .